Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies.

Trial Profile

Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2013

At a glance

  • Drugs Amuvatinib (Primary)
  • Indications Hodgkin's disease; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 01 Dec 2011 Actual patient number is 22 according to ClinicalTrials.gov record NCT00894894.
    • 01 Dec 2011 Actual patient number is 22 according to ClinicalTrials.gov record NCT00894894.
    • 18 Jan 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top